Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 96

1.

Thresholds of sea-level rise rate and sea-level rise acceleration rate in a vulnerable coastal wetland.

Wu W, Biber P, Bethel M.

Ecol Evol. 2017 Nov 12;7(24):10890-10903. doi: 10.1002/ece3.3550. eCollection 2017 Dec.

2.

Once-Weekly Exenatide and Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Hernandez AF.

N Engl J Med. 2017 Dec 21;377(25):2502. doi: 10.1056/NEJMc1714163. No abstract available.

3.

Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.

Bethel MA, Patel RA, Merrill P, Lokhnygina Y, Buse JB, Mentz RJ, Pagidipati NJ, Chan JC, Gustavson SM, Iqbal N, Maggioni AP, Öhman P, Poulter NR, Ramachandran A, Zinman B, Hernandez AF, Holman RR; EXSCEL Study Group.

Lancet Diabetes Endocrinol. 2018 Feb;6(2):105-113. doi: 10.1016/S2213-8587(17)30412-6. Epub 2017 Dec 6.

PMID:
29221659
4.

Modelling incremental benefits on complications rates when targeting lower HbA1c levels in people with Type 2 diabetes and cardiovascular disease.

Mostafa SA, Coleman RL, Agbaje OF, Gray AM, Holman RR, Bethel MA.

Diabet Med. 2018 Jan;35(1):72-77. doi: 10.1111/dme.13533. Epub 2017 Nov 16.

PMID:
29057545
5.

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.

Holman RR, Coleman RL, Chan JCN, Chiasson JL, Feng H, Ge J, Gerstein HC, Gray R, Huo Y, Lang Z, McMurray JJ, Rydén L, Schröder S, Sun Y, Theodorakis MJ, Tendera M, Tucker L, Tuomilehto J, Wei Y, Yang W, Wang D, Hu D, Pan C; ACE Study Group.

Lancet Diabetes Endocrinol. 2017 Nov;5(11):877-886. doi: 10.1016/S2213-8587(17)30309-1. Epub 2017 Sep 13.

PMID:
28917545
6.

Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.

Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, Chan JC, Choi J, Gustavson SM, Iqbal N, Maggioni AP, Marso SP, Öhman P, Pagidipati NJ, Poulter N, Ramachandran A, Zinman B, Hernandez AF; EXSCEL Study Group.

N Engl J Med. 2017 Sep 28;377(13):1228-1239. doi: 10.1056/NEJMoa1612917. Epub 2017 Sep 14.

PMID:
28910237
7.

Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus: International Insights From the TECOS Trial (Trial Evaluating Cardiovascular Outcomes With Sitagliptin).

Pagidipati NJ, Navar AM, Pieper KS, Green JB, Bethel MA, Armstrong PW, Josse RG, McGuire DK, Lokhnygina Y, Cornel JH, Halvorsen S, Strandberg TE, Delibasi T, Holman RR, Peterson ED; TECOS Study Group.

Circulation. 2017 Sep 26;136(13):1193-1203. doi: 10.1161/CIRCULATIONAHA.117.027252. Epub 2017 Jun 16.

PMID:
28626088
8.

Response to Sabour: Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders: methodological issues.

Abderhalden L, Weaver FM, Bethel M, Demirtas H, Burns S, Svircev J, Hoenig H, Lyles K, Miskevics S, Carbone LD.

Osteoporos Int. 2017 Jul;28(7):2261-2262. doi: 10.1007/s00198-017-4056-6. Epub 2017 May 15. No abstract available.

PMID:
28508089
9.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL).

Mentz RJ, Bethel MA, Gustavson S, Thompson VP, Pagidipati NJ, Buse JB, Chan JC, Iqbal N, Maggioni AP, Marso SP, Ohman P, Poulter N, Ramachandran A, Zinman B, Hernandez AF, Holman RR.

Am Heart J. 2017 May;187:1-9. doi: 10.1016/j.ahj.2017.02.005. Epub 2017 Feb 12.

PMID:
28454792
10.

Updated risk factors should be used to predict development of diabetes.

Bethel MA, Hyland KA, Chacra AR, Deedwania P, Fulcher GR, Holman RR, Jenssen T, Levitt NS, McMurray JJV, Boutati E, Thomas L, Sun JL, Haffner SM; NAVIGATOR Study Group.

J Diabetes Complications. 2017 May;31(5):859-863. doi: 10.1016/j.jdiacomp.2017.02.012. Epub 2017 Mar 2.

PMID:
28319004
11.

Association of Plasma SDF-1 with Bone Mineral Density, Body Composition, and Hip Fractures in Older Adults: The Cardiovascular Health Study.

Carbone LD, Bůžková P, Fink HA, Robbins JA, Bethel M, Hamrick MW, Hill WD.

Calcif Tissue Int. 2017 Jun;100(6):599-608. doi: 10.1007/s00223-017-0245-8. Epub 2017 Feb 28.

12.

Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study.

Carbone LD, Bůžková P, Fink HA, Robbins JA, Bethel M, Isales CM, Hill WD.

Osteoporos Int. 2017 May;28(5):1631-1640. doi: 10.1007/s00198-017-3916-4. Epub 2017 Feb 2.

13.

Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.

Currie G, Bethel MA, Holzhauer B, Haffner SM, Holman RR, McMurray JJV.

Diabetes Obes Metab. 2017 Jun;19(6):791-799. doi: 10.1111/dom.12877. Epub 2017 Mar 17.

PMID:
28093841
14.

Lnk Deficiency Leads to TPO-Mediated Osteoclastogenesis and Increased Bone Mass Phenotype.

Olivos DJ 3rd, Alvarez M, Cheng YH, Hooker RA, Ciovacco WA, Bethel M, McGough H, Yim C, Chitteti BR, Eleniste PP, Horowitz MC, Srour EF, Bruzzaniti A, Fuchs RK, Kacena MA.

J Cell Biochem. 2017 Aug;118(8):2231-2240. doi: 10.1002/jcb.25874. Epub 2017 Apr 18.

PMID:
28067429
15.

Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).

Bethel MA, Engel SS, Green JB, Huang Z, Josse RG, Kaufman KD, Standl E, Suryawanshi S, Van de Werf F, McGuire DK, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Apr;40(4):494-501. doi: 10.2337/dc16-1135. Epub 2017 Jan 5.

PMID:
28057693
16.

Dual-energy X-ray absorptiometry and fracture prediction in patients with spinal cord injuries and disorders.

Abderhalden L, Weaver FM, Bethel M, Demirtas H, Burns S, Svircev J, Hoenig H, Lyles K, Miskevics S, Carbone LD.

Osteoporos Int. 2017 Mar;28(3):925-934. doi: 10.1007/s00198-016-3841-y. Epub 2016 Dec 6.

PMID:
27924381
17.

Pancreatic Safety of Sitagliptin in the TECOS Study.

Buse JB, Bethel MA, Green JB, Stevens SR, Lokhnygina Y, Aschner P, Grado CR, Tankova T, Wainstein J, Josse R, Lachin JM, Engel SS, Patel K, Peterson ED, Holman RR; TECOS Study Group.

Diabetes Care. 2017 Feb;40(2):164-170. doi: 10.2337/dc15-2780. Epub 2016 Sep 14.

PMID:
27630212
18.

Sitagliptin and risk of fractures in type 2 diabetes: Results from the TECOS trial.

Josse RG, Majumdar SR, Zheng Y, Adler A, Bethel MA, Buse JB, Green JB, Kaufman KD, Rodbard HW, Tankova T, Westerhout CM, Peterson ED, Holman RR, Armstrong PW; TECOS Study Group.

Diabetes Obes Metab. 2017 Jan;19(1):78-86. doi: 10.1111/dom.12786. Epub 2016 Oct 6.

PMID:
27607571
19.

End-stage renal disease in patients with rheumatoid arthritis.

Paudyal S, Yang FM, Rice C, Chen CC, Skelton M, Bethel M, Brown S, Nahman NS Jr, Carbone L.

Semin Arthritis Rheum. 2017 Feb;46(4):418-422. doi: 10.1016/j.semarthrit.2016.07.016. Epub 2016 Aug 2.

PMID:
27591827
20.

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.

McGuire DK, Van de Werf F, Armstrong PW, Standl E, Koglin J, Green JB, Bethel MA, Cornel JH, Lopes RD, Halvorsen S, Ambrosio G, Buse JB, Josse RG, Lachin JM, Pencina MJ, Garg J, Lokhnygina Y, Holman RR, Peterson ED; Trial Evaluating Cardiovascular Outcomes With Sitagliptin (TECOS) Study Group.

JAMA Cardiol. 2016 May 1;1(2):126-35. doi: 10.1001/jamacardio.2016.0103.

PMID:
27437883

Supplemental Content

Loading ...
Support Center